Answers are grounded in this paper and cite their sources.
Randomized trial assesses long-term prostate cancer outcomes in men, highlighting screening's limited mortality benefits.
Current prostate cancer (PCa) screening guidelines for prostate-specific antigen (PSA) testing recommend informed discussions between patient and provider for men aged 55–69 years due to inconsistent trial results and benefit to harm ratio considerations. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial has followed participants for almost 30 years to assess the long-term impacts of screening, which can alter the balance of benefits and harms. For PCa screening, 76,678 men were randomized to a screening or usual care arm of the trial. PCa incidence and mortality were ascertained through active followup through 2009 and through linkages with cancer registries and the National Death Index, respectively, until 2021 and 2022. We compared incidence and mortality rates between screening arms and rates by stage and tumor grade for incidence. There was no significant difference in overall mortality rates (relative risk [RR], 0.93; 95% confidence interval [CI], 0.83–1.05) and incidence was borderline significantly higher in the screening arm (RR, 1.04; 95% CI, 1.00–1.07). There were significant reductions in the incidence of high grade (RR, 0.89; 95% CI, 0.81–0.98) and metastatic tumors (RR, 0.81; 95% CI, 0.66–0.98). Results from the PLCO have demonstrated long-term impacts of PSA screening but no significant reduction in PCa mortality.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: